Rezolute, Inc.’s Post

The FDA is now asking for all CAR-T cell products on the market to have a boxed warning for the risk of T-cell malignancies.  Based on the data we have available so far, is it very likely that CAR-T therapy caused most or all of these malignancies.  With 22 reported cases and more than 27,000 doses of CAR-T administered in the US, it appears to occur in about 1 in 1200 patients or so.  T cells are generally thought to have a low risk of transformation, so this incidence rate is fairly high, even if these patients are at higher risk. In addition, in the three patients where the testing was done, the T cell malignancies were CAR positive.  It does raise the question of whether there are ways to improve the manufacturing process to reduce the rate of these T-cell malignancies, and how they developed in the first place.  Was there an underlying malignant clone, or did it occur during the manufacturing process? #multiplemyeloma #dlbcl #fda https://lnkd.in/eRCXxHCa

📰Published in the Thrombosis Journal, this study aimed to evaluate the association of antiphospholipid antibodies & conventional markers of coagulation with ischemic &🩸risk in patients with AF undergoing PCI. READ➡️https://lnkd.in/eKAhytSD #coagulation #clinicalstudy #HeartHealth #cardiovascular

When we will be able to reverse atherosclerosis? Brilliant as ever talk by Matthew O'Connor Not all cholesterol is bad, but let’s talk about 7KC – it’s the real villain here. Macrophages can’t “clean” it from blood vessel walls, so they turn into foam cells. Cyclodextrins, a class of compounds, have the potential to “cleanse” cholesterol, but they also come with toxicity concerns. Cyclarity Therapeutics is doing groundbreaking work in modifying this class of compounds, and the drugs they’re developing could truly revolutionize the treatment of cardiovascular diseases. Their lead compound, UDP-003, has the ability to prevent changes caused by 7KC at a molecular level, essentially reversing atherosclerotic changes reversing existing plaques! This year, the company is kicking off clinical trials involving 72 healthy volunteers and 12 patients post cardiac events. Phase 2 trials are slated for the end of 2027. #aging #CVD #cholesterol

Fatigue, abnormal temperature, elevated heart rate. These are all elusive and vague symptoms that could imply a variety of conditions—including sepsis. Explore the science of Monocyte Distribution Width (MDW), a novel parameter for early sepsis detection and intervention in adult ED patients that’s part of a CBC-Diff on DxH 900 and 690T hematology analyzers. Learn More: https://bit.ly/3sIBkmV #WorldSepsisDay #WSD #SepsisAwareness #Sepsis #StopSepsis #SaveLives #ED #MDW

Fatigue, abnormal temperature, elevated heart rate. These are all elusive and vague symptoms that could imply a variety of conditions—including sepsis. Explore the science of Monocyte Distribution Width (MDW), a novel parameter for early sepsis detection and intervention in adult ED patients that’s part of a CBC-Diff on DxH 900 and 690T hematology analyzers. Learn More: https://bit.ly/3sIBkmV #WorldSepsisDay #WSD #SepsisAwareness #Sepsis #StopSepsis #SaveLives #ED #MDW

Paltusotine, an investigational, first-in-class, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894 a first-in-class, investigational, oral ACTH antagonist, that is currently in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing’s disease. #Congenitaladrenalhyperplasia #Cushingdisease #ACTHantagonist #Drugdevelopment #Innovation #Acromegaly #Firstinclass

#Trending on #RadTwitter 1. #PSMA PET/CT Identifies More #RenalCancer than CT https://lnkd.in/exPakg9f 2. New Research on Abbreviated Breast #MRI and DBT in #DenseBreasts https://lnkd.in/euikeKky 3. FDA Clears AI-Powered CT Assessment Tool for Lung Fibrosis https://lnkd.in/gD4TVpFT

May is Stroke Awareness Month! 🧠❤️ Let's come together to spread awareness about preventing recurrent strokes and supporting survivors. Did you know that for some patients, DAPT (Dual Antiplatelet Therapy) can significantly reduce the risk of recurrent strokes? (1) By assessing an individual's CYP2C19 genotype, their DAPT therapy can be further optimized to ensure effective treatment. (2) Discover how Genomadix is paving the way for personalized DAPT guidance for stroke patients. Visit Genomadix | Molecular testing. Where and When you need it to learn more. #StrokeAwarenessMonth #DAPT #Pharmacogenetics #PrecisionMedicine 1. Kleindorfer DO, et al. Stroke. 2021;52:e364–e467. 2. Lee CR, et al. J Clinical Pharmacol Therapeutics. 2022;122(5):959-967.

Fatigue, abnormal temperature, elevated heart rate. These are all elusive and vague symptoms that could imply a variety of conditions—including sepsis. Explore the science of Monocyte Distribution Width (MDW), a novel parameter for early sepsis detection and intervention in adult ED patients that’s part of a CBC-Diff on DxH 900 and 690T hematology analyzers. Learn More: https://bit.ly/3sIBkmV #WorldSepsisDay #WSD #SepsisAwareness #Sepsis #StopSepsis #SaveLives #ED #MDW

Jo 1 or histidyl tRNA synthetase are enzymes found in all nucleated cells. Anti-Jo-1 antibodies are associated with Polymyositis (PM) and Dermatomyositis (DM), both of which are inflammatory myopathies with immunologic abnormalities. This antibody has been found in 20-30% of patients with PM/DM, and in more than 60% of patients with PM. Learn more about the testing with Medical Database. https://lnkd.in/dbWznWcC #medicaldatabase